Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 40 results:
Συντάκτης [ Τίτλος(Asc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Panidis, Dimitrios  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
Koiou, E., Tziomalos K., Katsikis I., Kandaraki E. A., Kalaitzakis E., Delkos D., et al. (2012).  Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.. Gynecol Endocrinol. 28(1), 20-4.
U
Panidis, D., Tziomalos K., Papadakis E., Vosnakis C., Betsas G., Tsourdi E., et al. (2014).  Uterine volume and endometrial thickness in the early follicular phase in patients with polycystic ovary syndrome.. Endocr Pract. 20(6), 540-7.
S
Christopoulos, P., Mastorakos G., Gazouli M., Deligeoroglou E., Katsikis I., Diamanti-Kandarakis E., et al. (2010).  Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact?. Gynecol Endocrinol. 26(9), 698-703.
Vosnakis, C., Georgopoulos N. A., Armeni A. K., Papadakis E., Roupas N. D., Katsikis I., et al. (2012).  Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.. Eur J Obstet Gynecol Reprod Biol. 163(2), 185-9.
Makedos, A., Goulis D. G., Papanikolaou A., & Panidis D. (2010).  Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.. Angiology. 61(6), 595-601.
Diamanti-Kandarakis, E., Livadas S., Katsikis I., Piperi C., Mantziou A., Aimilia M., et al. (2011).  Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome.. J Bone Miner Metab. 29(2), 201-6.
Panidis, D., Katsikis I., Karkanaki A., Piouka A., Armeni A. K., & Georgopoulos N. A. (2011).  Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels.. Med Hypotheses. 77(4), 649-53.
Georgopoulos, N. A., Saltamavros A. D., Decavalas G., Piouka A., Katsikis I., & Panidis D. (2010).  Serum AMH, FSH, and LH levels in PCOS.. Fertil Steril. 93(3), e13; author reply e14.
Chatzimeletiou, K., Sioga A., Oikonomou L., Charalampidou S., Kantartzi P., Zournatzi V., et al. (2011).  Semen analysis by electron and fluorescence microscopy in a case of partial hydatidiform mole reveals a high incidence of abnormal morphology, diploidy, and tetraploidy.. Fertil Steril. 95(7), 2430.e1-5.
R
Panidis, D., Tziomalos K., Papadakis E., Chatzis P., Kandaraki E. A., Tsourdi E. A., et al. (2014).  The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.. Clin Endocrinol (Oxf). 80(3), 432-8.
P
Panidis, D., Macut D., Tziomalos K., Papadakis E., Mikhailidis K., Kandaraki E. A., et al. (2013).  Prevalence of metabolic syndrome in women with polycystic ovary syndrome.. Clin Endocrinol (Oxf). 78(4), 586-92.
Koiou, E., Tziomalos K., Katsikis I., Papadakis E., Kandaraki E. A., & Panidis D. (2013).  Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.. Gynecol Endocrinol. 29(3), 250-3.
Koiou, E., Tziomalos K., Katsikis I., Dinas K., Tsourdi E. A., Kandaraki E. A., et al. (2012).  Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.. Hormones (Athens). 11(1), 77-85.
Koiou, E., Tziomalos K., Dinas K., Katsikis I., Kandaraki E. A., Tsourdi E., et al. (2012).  Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.. Endocr J. 59(1), 21-9.
Katsikis, I., Karkanaki A., Misichronis G., Delkos D., Kandaraki E. A., & Panidis D. (2011).  Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.. Eur J Obstet Gynecol Reprod Biol. 156(2), 181-5.
Koiou, E., Dinas K., Tziomalos K., Toulis K., Kandaraki E. A., Kalaitzakis E., et al. (2011).  The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria.. Obes Facts. 4(2), 145-50.
O
Katsikis, I., Mouslech T., Kourtis A., Panidis D., & Georgopoulos N. A. (2009).  Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance.. Fertil Steril. 91(4), e3; author reply e4.
N
Polyzos, S. A., Goulis D. G., Kountouras J., Mintziori G., Chatzis P., Papadakis E., et al. (2014).  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.. Hormones (Athens). 13(4), 519-31.
L
Panidis, D., Tziomalos K., Papadakis E., Vosnakis C., Chatzis P., & Katsikis I. (2013).  Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.. Endocrine. 44(3), 583-90.
I
Panidis, D., Tziomalos K., Misichronis G., Papadakis E., Betsas G., Katsikis I., et al. (2012).  Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.. Hum Reprod. 27(2), 541-9.
Panidis, D., Georgopoulos N. A., Piouka A., Katsikis I., Saltamavros A. D., Decavalas G., et al. (2011).  The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.. Gynecol Endocrinol. 27(8), 587-92.
H
Karkanaki, A., Vavilis D., Traianos A., Kalogiannidis I., & Panidis D. (2010).  Hormone therapy and asymmetrical dimethylarginine in postmenopausal women.. Hormones (Athens). 9(2), 127-35.
G
Panidis, D., Tziomalos K., Papadakis E., Kandaraki E. A., & Katsikis I. (2013).  The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require r. Hormones (Athens). 12(2), 192-200.
E
Daskalopoulos, G., Karkanaki A., Piouka A., Prapas N., Panidis D., Gkeleris P., et al. (2015).  Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.. Curr Vasc Pharmacol. 13(6), 788-800.
Panidis, D., Tziomalos K., Koiou E., Kandaraki E. A., Tsourdi E., Delkos D., et al. (2010).  The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study.. Reprod Biol Endocrinol. 8, 151.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές